ArticleCancer medicine2026
Astragalus Polysaccharides Induce Immunogenic Cell Death in Melanoma: A Mechanism Mediated by cGAS/STING Activation via Intratumoral Microbiota Modulation.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Astragalus polysaccharides (APS) exhibits potent immunomodulatory properties, yet its interplay with intratumoral microbiota in driving antitumor immunity remains elusive. Herein, we demonstrate that APS suppresses melanoma growth and prolongs survival by inducing immunogenic cell death (ICD) via the cGAS-STING pathway. Inhibition of cGAS-STING abrogated APS efficacy. Notably, depletion of intratumoral microbiota using antibiotics blunted APS-mediated cGAS-STING activation and immune responses, confirming a microbiota-dependent mechanism. 5R 16S rRNA sequencing identified Pseudomonas enrichment as a distinct signature of APS treatment. Crucially, administration of Pseudomonas sterile supernatant was sufficient to activate cGAS-STING signaling, induce ICD, and inhibit tumor growth in microbiota-depleted mice. We propose that APS acts as an upstream modulator that enriches Pseudomonas, creating a microenvironment where bacterial secretions trigger the cGAS-STING pathway to induce ICD. These findings provide a novel theoretical basis for microbiota-targeted immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.